pharma · Advanced Or Metastatic Merkel Cell Carcinoma · Cutaneous Melanoma, Stage III · HURA
TuHURA Biosciences, Inc./NV
TuHURA Biosciences is a pharma organization headquartered in Tampa, USA. It trades on NYSE under ticker HURA. Primary therapeutic focus areas include Advanced Or Metastatic Merkel Cell Carcinoma, Cutaneous Melanoma, Stag
Tampa, USA HQ
1996 Founded
32 Employees
Public company Type
HURA · NYSE Ticker
Company details
- Status
- Public
- HQ
- Tampa, USA
- Founded
- 1996
- Employees
- 32
- Programs
- 4
- Drugs
- 0
- Patents
- 0
IFx-Hu2.0
Phase 1 · mab · Cutaneous Melanoma, Stage III
IFx-Hu2.0 for Cutaneous Melanoma, Stage III is a Phase 1 program (mab) at TuHURA Biosciences, Inc./NV with 1 ClinicalTrials.gov record(s).
Internal code CM 2017-01
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- TuHURA Biosciences, Inc./NV
- Phase
- Phase 1
- Modality
- mab
- Indication
- Cutaneous Melanoma, Stage III
- Status
- completed
- Trials
- 1